Cargando…
New therapeutic agents in diabetic nephropathy
Studies investigating diabetic nephropathy (DN) have mostly focused on interpreting the pathologic molecular mechanisms of DN, which may provide valuable tools for early diagnosis and prevention of disease onset and progression. Currently, there are few therapeutic drugs for DN, which mainly consist...
Autores principales: | Kim, Yaeni, Park, Cheol Whee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5214729/ https://www.ncbi.nlm.nih.gov/pubmed/28049280 http://dx.doi.org/10.3904/kjim.2016.174 |
Ejemplares similares
-
Response to comment on “New therapeutic agents in diabetic nephropathy”
por: Kim, Yaeni, et al.
Publicado: (2017) -
Adenosine monophosphate–activated protein kinase in diabetic nephropathy
por: Kim, Yaeni, et al.
Publicado: (2016) -
Mechanisms of Adiponectin Action: Implication of Adiponectin Receptor Agonism in Diabetic Kidney Disease
por: Kim, Yaeni, et al.
Publicado: (2019) -
Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy
por: Chung, Sungjin, et al.
Publicado: (2011) -
Can management of the components of metabolic syndrome modify the course of chronic kidney disease?
por: Kim, Yaeni, et al.
Publicado: (2020)